Lantheus Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
8.1%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
$5.60next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Oncology Revenue (PYLARIFY Sales) Quarterly240.9MTarget: Sustain market leadership in PSMA PET imaging and execute PYLARIFY TruVu conversion starting Q4 2026
Cardiology Revenue (DEFINITY Sales) Quarterly84.6MTarget: Maintain >80% market share and steady volume-driven growth
Neurology Revenue (Neuraceq Sales) Quarterly35.4MTarget: Expand PMF manufacturing footprint beyond 22 sites to capture Alzheimer's imaging market
Watch Items
- Takeover Proposal and Strategic AlternativesTrigger: Definitive agreement or termination of discussions regarding the $7 billion acquisition proposal from CuriumAction: Re-evaluate standalone valuation models, cost of capital, and long-term growth assumptions based on transaction terms
- Permanent CEO AppointmentTrigger: Announcement of a permanent successor to Interim CEO Mary Anne HeinoAction: Assess the new leadership's strategic alignment, operational background, and potential changes to capital allocation priorities
- PNT2003 Regulatory and Legal ResolutionTrigger: Expiration of the 30-month Hatch-Waxman patent litigation stay in June 2026Action: Monitor final FDA approval status and commercial launch readiness for the Lutetium Lu 177 Dotatate radioequivalent
Research as of 19 Jun 2026